Dominance of EGFR and insignificant KRAS mutations in prediction of Tyrosin-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status

Abstract

Authors confirmed significant positive predictive value of EGFR mutations for tyrosinkinase inhibitor therapy, while KRAS mutations were not found as negative predictor of survival in such conditions.

Keywords

• Tyrosin-kinase therapy
• tumor subtype
• smoking status